Summary
The uricosuric effect of DuP-753, a novel, specific angiotensin II receptor antagonist, has been explored in a healthy male Japanese volunteers, given single oral doses of 25, 50, 100 or 200 mg (n=6), or 100 mg (n=6) or placebo (n=3) once daily for 7 consecutive days.
In the single-dose study, serum uric acid measured at 4 h after dosing showed a dose dependent decrease; the reductions from the corresponding pre-dose values were: 0.32 (25 mg), 0.77 (50 mg), 1.25 (100 mg) and 1.33 mg dl−1 (200 mg). The urinary excretion of uric acid within the first 4 h after treatment was also increased in a dose-dependent manner, whereas the urinary excretion of creatinine remained unchanged.
In the multiple-dose study, DuP-753 significantly decreased the serum uric acid concentration measured 4 h both after the first (pre-dose value: 5.68 vs 4 h after: 4.48 mg·dl−1) and last administrations (4.42 mg·dl−1). Simultaneously, the ratio of urinary uric acid to creatinine excretion was significantly increased within the first 4 h both after the first (DuP-753: 1.190 vs placebo: 0.576) and last administrations (1.02 vs 0.576).
The findings suggest that DuP-753 posesses a uricosuric effect both after single and multiple doses in healthy subjects. The effect should be further examined in hypertensive patients.
Article PDF
Avoid common mistakes on your manuscript.
References
Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PBMWM (1990) Non-peptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP-753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252: 711–718
Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM (1990) Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP-753, an orally active anti-hypertensive agent. J Pharmacol Exp Ther 252: 719–725
Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PBMWM (1990) Non-peptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP-753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252: 726–732
Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH (1966) Hyperuricemia in primary and renal hypertension. N Engl J Med 275: 457–464
Breckenridge A (1966) Hypertension and hyperuricemia. Lancet 1: 1518
Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG (1980) Serum uric acid in essential hypertension: An inducer of renal vascular involvement. Ann Intern Med 93: 817–821
Mustard JF, Murphy EA, Ogryzlo MA, Smythe HA (1963) Blood coagulation and platelet economy in subjects with primary gout. Can Med J 89: 1207–1211
Emmerson BT (1980) Uricosuric diuretics. Kidney Int 18: 677–685
Streeten DHP, Anderson GH. Jr (1984) Angiotensin-receptor blocking drugs. In: Doyle AE (ed) Handbook of hypertension, vol. 5; Clinical pharmacology of antihypertensive drugs. Elsevier, Amsterdam, pp 246–271
Wong PC, Price WA, Dhiu AT, Carini DJ, Duncia JV, Johnson AL, Wexler RR, Timmermans PBMWM (1990) Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP-753. Hypertension 15: 823–834
Levinson DJ, Sorensen LB (1980) Renal handling of uric acid in normal and gouty subjects: evidence for a 4-component system. Ann Rheum Dis 39: 173–179
Cogan MG, Liu F-Y (1990) Angiotensin II: A powerful controller of sodium transport in the early proximal tubule. Hypertension 15: 451–458
Xie M-H, Liu F-Y, Wong PC, Timmermans PBMWM, Cogan MG Proximal nephron and renal effects of DuP-753, a nonpeptide angiotensin II receptor antagonist. Kidney Int (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakashima, M., Uematsu, T., Kosuge, K. et al. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42, 333–335 (1992). https://doi.org/10.1007/BF00266358
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00266358